2024
Incidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers
Dey P, Kc M, Proussaloglou E, Khubchandani J, Kim L, Zanieski G, Park T, Lynch M, Gillego A, Valero M, Schneider E, Golshan M, Greenup R, Berger E. Incidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers. Annals Of Surgical Oncology 2024, 31: 8821-8828. PMID: 39240394, DOI: 10.1245/s10434-024-16124-9.Peer-Reviewed Original ResearchTriple-negative breast cancerClinically node-negativePathologically node-negativePN+ diseaseNode-negativeBreast cancerYears of ageNodal diseaseHR-/HER2Significant comorbiditiesEpidermal growth factor receptor 2-positiveOdds of node positivityRate of nodal diseaseTriple-positive breast cancerTriple positive breast cancerEarly-stage breast cancerHR-positive/HER2-negativePathologic nodal diseasePathologic nodal positivityPredictors of pN+T1a breast cancerHR-/HER2+Sentinel node biopsyNational Cancer DatabasePathologic nodal stage
2023
Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023?
Myers A, Briganti A, Leibovich B, Lerner S, Moschini M, Rouprêt M, Shariat S, Spiess P, Stenzl A, Taneja S, Touijer K, Kamat A. Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? European Urology Oncology 2023, 7: 412-420. PMID: 37980250, DOI: 10.1016/j.euo.2023.10.028.Peer-Reviewed Original ResearchLymph node dissectionNode dissectionPatient selectionGenitourinary cancersCurrent evidencePathologic nodal stageJudicious patient selectionAdjuvant treatmentNodal stageCollaborative reviewGenitourinary malignanciesTestis cancerTherapeutic benefitDissectionCancerLymphadenectomyLymphHighlight knowledge gapsReference standardContemporary evidenceOngoing areaCumulative benefitsEvidenceSurgeryPenile
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply